Secondary Hypertension — Comprehensive Research Report

Prepared: 2026-09-01 Target concept: Secondary Hypertension MONDO: MONDO:0001200 (secondary hypertension) — resolved live against EBI OLS4 Category: Complex (multi-etiology; heterogeneous)

How to read the citations in this report

Citations fall into three tiers, and they are not interchangeable for dismech evidence purposes:

Two candidate PMIDs I tested came back as entirely different papers (17174708 → a Lancet paper on generalised anxiety disorder; 18445663 → a BMI/aldosterone correlation study). That is the exact "real-but-wrong identifier" failure mode. Everything marked ✔ below was checked one by one.

1. Disease Information

1.1 Overview

Secondary hypertension is arterial hypertension arising from an identifiable, and frequently correctable, underlying cause — as opposed to primary (essential) hypertension, where no single cause is demonstrable. The distinction is not academic bookkeeping: correcting the upstream lesion can cure the blood pressure elevation outright, or convert an unmanageable resistant hypertension into a treatable one. Think of it as the difference between a leaking pipe and a house built on a slope. Both give you a wet basement; only one is fixed by fixing the pipe.

The clinically operational definition has three parts: 1. Confirmed hypertension (office BP plus out-of-office confirmation — ABPM or home BP). 2. A demonstrable causal condition (endocrine, renal, vascular, neurogenic, pharmacologic, or monogenic). 3. Plausible temporal/mechanistic linkage, ideally with BP improvement on treating the cause.

1.2 Identifiers

1.3 Synonyms

Secondary arterial hypertension · non-essential hypertension · secondary HTN · secondary high blood pressure · hypertension of known cause · (historically) "curable hypertension"

1.4 Nature of the evidence base

Mixed, and the mix matters. Prevalence estimates come from two very different kinds of study:

• Systematic-screening cohorts in referral hypertension centers (individual-patient level, protocol-driven) — these produce the high prevalence figures.
• Population/registry/claims data — these produce the low figures, because they only capture causes somebody bothered to look for.

The gap between them is the single most important epidemiological fact in this whole area, and I return to it in §9.

2. Etiology

2.1 Causal architecture

Secondary hypertension has no single etiology. It is a convergence phenotype: many distinct upstream lesions funnel into a shared final common pathway of raised systemic arterial pressure, in the same way that many separate injuries funnel into "fever." The upstream lesions sort into six families:

A. Endocrine - Primary aldosteronism (PA) — by a wide margin the leading cause. Aldosterone-producing adenoma, bilateral idiopathic hyperaldosteronism, unilateral hyperplasia, aldosterone-producing micronodules, rare adrenocortical carcinoma, and familial forms FH-I through FH-IV. - Pheochromocytoma / paraganglioma (PPGL) — catecholamine-secreting chromaffin tumors. - Cushing syndrome / disease — cortisol excess (ACTH-dependent or independent). - Congenital adrenal hyperplasia, specifically 11β-hydroxylase (CYP11B1) and 17α-hydroxylase (CYP17A1) deficiency — the two "hypertensive" CAH variants. - Thyroid dysfunction — hyperthyroidism (systolic hypertension, wide pulse pressure) and hypothyroidism (diastolic hypertension, raised systemic vascular resistance). - Primary hyperparathyroidism — hypertension in ~20% of patients ○ SOURCED. - Acromegaly — growth hormone/IGF-1 excess with sodium retention.

B. Renal - Renal parenchymal disease — chronic glomerulonephritis, diabetic nephropathy, polycystic kidney disease, reflux nephropathy, CAKUT, chronic interstitial nephritis. Dominant in children. - Renovascular disease — atherosclerotic renal artery stenosis (older, diffuse atherosclerosis) and fibromuscular dysplasia (younger, female-predominant). - Renin-secreting juxtaglomerular tumor (very rare), Page kidney (subcapsular hematoma compressing parenchyma).

C. Vascular / mechanical - Coarctation of the aorta — including recoarctation after repair. Classically upper-limb hypertension with a radiofemoral delay. - Large-vessel arteritis (Takayasu, giant cell) involving renal or aortic segments. - Mid-aortic syndrome.

D. Neurogenic / sleep - Obstructive sleep apnea — extremely common and frequently the reason a hypertension is "resistant." - Raised intracranial pressure, brainstem compression (neurovascular conflict at the RVLM), autonomic dysreflexia after spinal cord injury, baroreflex failure.

E. Drug- and toxin-induced (the "iatrogenic and ingested" family — most directly relevant to a toxicology-flavored curation) - NSAIDs (COX-2 mediated renal sodium retention) - Combined oral contraceptives / estrogen-containing preparations - Glucocorticoids and mineralocorticoids - Calcineurin inhibitors (ciclosporin, tacrolimus) - VEGF/VEGFR pathway inhibitors (bevacizumab, sunitinib, sorafenib, pazopanib) — near-class-effect hypertension - Erythropoiesis-stimulating agents - Sympathomimetics: decongestants, amphetamines, cocaine, MDMA - SNRIs/venlafaxine, MAOI + tyramine - Alcohol (dose-dependent), liquorice / glycyrrhizic acid (11β-HSD2 inhibition → acquired apparent mineralocorticoid excess) - Herbal ephedra, yohimbine, high-dose caffeine

F. Monogenic / Mendelian — see §4.

2.2 Relative frequency of causes (the headline recent dataset)

✔ VERIFIED — de Freminville JB, Gardini M, Cremer A, et al. "Prevalence and Risk Factors for Secondary Hypertension in Young Adults." Hypertension. 2024. PMID:39297209. DOI:10.1161/HYPERTENSIONAHA.124.22753

Cross-sectional study of 2,090 hypertensive patients aged 18–40:

Reported quotes (re-verify before use as snippets): "29.6%" had secondary hypertension; the authors concluded "all patients with hypertension under 40 years of age should be screened for secondary causes."

Two things in that dataset deserve emphasis for a knowledge base: 1. BP severity did not stratify risk. "Blood pressure levels below 160/100 mm Hg did not correlate with lower secondary hypertension rates." The common clinical heuristic — screen only the severe ones — fails here. 2. Risk factors were counterintuitive: female sex, low potassium, multiple antihypertensive medications, absence of a family history of hypertension, normal body weight, and diabetes. Normal weight and no family history raise suspicion because they remove the usual explanations for essential hypertension.

2.3 Risk factors

Genetic risk factors - Monogenic causal variants (see §4) — full penetrance for the hypertension phenotype in most. - Germline PPGL-susceptibility variants (SDHB, SDHD, SDHC, SDHA, SDHAF2, RET, VHL, NF1, MAX, TMEM127, FH) — 25–40% of all PPGL carry a pathogenic germline variant ○ SOURCED. - Familial hyperaldosteronism types I–IV. - Polygenic background modulating expression of any of the above (shared with essential hypertension: NPPA/NPPB, UMOD, CYP17A1, ATP2B1 loci — GWAS Catalog).

Environmental / acquired risk factors - Age — bimodal. High secondary fraction in the very young (renal/vascular) and in the elderly (atherosclerotic RAS, drug burden). - Obesity — drives OSA, and independently raises aldosterone. Note the paradox: in the young-adult cohort, normal weight predicted secondary hypertension, because obesity offers a competing explanation. - Dietary sodium — the permissive substrate for every mineralocorticoid-excess mechanism. - Alcohol — dose-dependent pressor effect. - Smoking / atherosclerotic risk factors — for atherosclerotic renovascular disease. - Female sex — for fibromuscular dysplasia (30s–40s, normal renal function) ○ SOURCED, and in the young-adult secondary hypertension cohort ✔. - Occupational/environmental toxicants — lead and cadmium exposure (nephrotoxic, chronic), noise and air pollution (sympathetic activation). - Pregnancy — unmasks Geller syndrome (progesterone-activated MR); preeclampsia is a distinct entity but overlaps mechanistically. - Solid organ transplantation — calcineurin inhibitors, hypertension in 32–81% of renal transplant recipients on ciclosporin, approaching ~100% in cardiac transplant recipients ○ SOURCED.

Protective factors - Genetic: loss-of-function variants in the opposite direction of the disease genes — e.g. ENaC loss-of-function (pseudohypoaldosteronism type 1), NCC loss-of-function (Gitelman), NKCC2/ROMK loss-of-function (Bartter). These lower blood pressure and are the natural mirror image of Liddle and Gordon syndromes. Heterozygous carriers of Bartter/Gitelman alleles show lower BP at population level ○ SOURCED (the classic Ji et al. 2008 Nat Genet observation — resolve the PMID before citing). - Environmental: sodium restriction, potassium-rich diet, weight loss, CPAP adherence in OSA, alcohol reduction, avoidance of the pressor drug classes in §2.1E.

Gene–environment interactions - Salt × mineralocorticoid genotype is the archetype: Liddle syndrome, GRA, AME, and Gordon syndrome are all conditionally hypertensive — the phenotype requires dietary sodium. Restrict sodium and the pressure falls, because the gain-of-function is in a sodium-reabsorption pathway with nothing to reabsorb. - Liquorice × HSD11B2 genotype: heterozygous HSD11B2 carriers are disproportionately sensitive to glycyrrhizic acid — a pharmacologic phenocopy of a genetic disease. A clean two-hit gene–environment model. - VEGF inhibitor × baseline endothelial reserve: pre-existing hypertension and endothelial dysfunction predict severity of VEGFi-induced hypertension ○ SOURCED. - Obesity × aldosterone: adiposity independently raises aldosterone secretion, so obesity both mimics and aggravates PA ○ SOURCED (Rossi 2008, PMID:18445663 ✔ — BMI independently predicted plasma aldosterone concentration in primary hypertension, β=0.153, P<0.0001, though notably not in the PA group, and this did not degrade ARR diagnostic accuracy).

3. Phenotypes

Important caveat on the HPO IDs below. I am giving labels I am confident in and CURIEs at two confidence levels. Anything marked △ is a lead — do not bind it without runoak -i sqlite:obo:hp info confirmation. Per this project's own rules, a plausible-but-wrong CURIE is worse than no CURIE.

3.1 Core phenotype

3.2 Laboratory abnormalities (the diagnostic tells)

3.3 Symptoms and signs by cause

• PA: frequently asymptomatic apart from the hypertension. Muscle weakness (HP:0001324), cramps, polyuria (HP:0000103), polydipsia (HP:0001959), nocturia — all downstream of hypokalemia and impaired renal concentrating ability.
• PPGL: the classic triad — episodic headache (HP:0002315), palpitations (HP:0001962), diaphoresis (HP:0000975 hyperhidrosis). Paroxysmal, episodic course; pallor, tremor, anxiety, orthostatic hypotension between spells. "PPGL could produce catecholamines such as epinephrine, norepinephrine, and dopamine leading to clinical presentation of hypertension, headache, diaphoresis, palpitations" ○ SOURCED. Roughly half have sustained rather than paroxysmal hypertension.
• Cushing syndrome: central obesity, moon facies, violaceous striae, proximal myopathy, easy bruising, glucose intolerance, osteoporosis. △ on all CURIEs.
• OSA: witnessed apneas (HP:0002870 obstructive sleep apnea, confident), snoring, excessive daytime somnolence, nocturnal hypertension and non-dipping BP — this last one is the pathognomonic pattern rather than a symptom.
• Coarctation: upper-limb hypertension with diminished/delayed femoral pulses, interscapular murmur, claudication, rib notching on chest radiograph.
• Renovascular: abdominal bruit, flash pulmonary edema (Pickering syndrome, bilateral disease), acute kidney injury on starting an ACE inhibitor or ARB — a genuinely useful provocative sign.
• Thyroid: hyperthyroid — weight loss, heat intolerance, tremor, tachycardia, systolic hypertension, exophthalmos; hypothyroid — fatigue, weight gain, cold intolerance, diastolic hypertension ○ SOURCED.

3.4 Target-organ damage phenotypes (shared downstream)

Left ventricular hypertrophy (HP:0001712), heart failure (HP:0001635), atrial fibrillation (△), ischemic and hemorrhagic stroke (HP:0002140 / △), hypertensive retinopathy (△), CKD progression (HP:0012622), aortic dissection/ectasia (△).

These are disproportionately severe in secondary hypertension, especially PA, and are not fully explained by the BP level itself — see §6.2 and §11.

3.5 Quality of life

• PA specifically: adrenalectomy "greatly improves quality of life by resolving hypertension, hypokalemia, and associated symptoms" ○ SOURCED. QoL improvement after surgical cure is a consistently reported outcome and one of the better arguments for aggressive case-finding.
• OSA: daytime somnolence, cognitive impairment, and accident risk carry QoL burden independent of the BP.
• Drug-induced: forces the oncology/transplant/rheumatology trade-off — dose-reduce the culprit or accept the BP.
• Instruments in use: SF-36, EQ-5D, RAND-36 in PA cohorts; ESS and FOSQ in OSA.

4. Genetic / Molecular Information

4.1 Monogenic (Mendelian) hypertension — the causal gene table

All gene symbols below are HGNC-approved. I have deliberately not written HGNC numeric IDs — those must come from an HGNC lookup, not from recall.

PPGL germline frequency ○ SOURCED: "Pheochromocytoma and paragangliomas carry 25–40% pathogenic germline gene variants." A 2023 cohort reported RET 38.3%, VHL 21.3%, SDHB and NF1 17% each; another analysis put total germline-plus-somatic explanation "up to about 60%." Germline SDHB and VHL variants were found exclusively in patients under 30, and bilateral disease exclusively in VHL carriers ○ — both directly actionable for a testing-strategy annotation.

4.2 Somatic variants — aldosterone-producing adenomas

This is one of the tidiest genotype–phenotype stories in endocrine oncology. >90% of aldosterone-producing adenomas carry a somatic driver ○ SOURCED, and every driver converges on the same cell-physiology endpoint: depolarization of the zona glomerulosa cell → Ca²⁺ influx → constitutive CYP11B2 transcription → autonomous aldosterone.

Ancestry and sex structure the mutation spectrum: "Somatic CACNA1D gene mutations are particularly more prevalent in black males whereas KCNJ5 gene mutations are most frequently present in black females" ○ SOURCED. KCNJ5 dominance is much higher in East Asian cohorts (Taiwanese series: 59.5% ○).

Clinical correlate ○ SOURCED: KCNJ5-mutant APAs are associated with "a worse baseline status and better recovery of left ventricular remodeling and diastolic function" after treatment — worse going in, better coming out.

4.3 Modifier genes

• Renin–angiotensin polymorphisms (AGT M235T, ACE I/D) modulate severity of renovascular and salt-sensitive phenotypes.
• HSD11B2 heterozygosity as a liquorice-sensitivity modifier.
• CYP3A5 expressor status affects tacrolimus dosing and therefore calcineurin-inhibitor hypertension exposure — a pharmacogenomic modifier.
• Polygenic BP score adds to monogenic burden (relevant for FH-I penetrance variability).

4.4 Epigenetics

• Adrenal CYP11B2 expression is regulated by promoter methylation; hypomethylation is reported in APA relative to adjacent cortex ○ SOURCED (verify specific PMID).
• Renal HSD11B2 promoter methylation is a candidate mechanism for acquired salt sensitivity ○.
• Chronic intermittent hypoxia (OSA) induces persistent epigenetic changes in carotid body and adrenal medulla — the proposed substrate for "BP memory" after OSA treatment ○.
• This is the least mature area in the whole report. Treat it as a knowledge gap rather than a curatable mechanism.

4.5 Chromosomal abnormalities

• Turner syndrome (45,X) — coarctation, bicuspid aortic valve, and hypertension. A genuine chromosomal cause of secondary hypertension.
• The GRA chimeric gene is itself a structural rearrangement (unequal crossover at 8q24.3) detectable by long-range PCR / MLPA.
• Otherwise not a major etiologic category.

5. Environmental Information

5.1 Environmental and toxicant factors

5.2 Drug-induced hypertension (mechanistic detail)

This family deserves its own mechanistic treatment because it is the one where dismech can model a toxicologic causal chain end-to-end.

• NSAIDs — "The hypertensive effect of NSAIDs is dose dependent and probably involves inhibition of COX-2 in the kidneys, which reduces sodium excretion and increases intravascular volume." Indomethacin, naproxen and piroxicam produce the largest rises ○ SOURCED.
• Combined oral contraceptives — historical literature reports new hypertension in ~5% of users; modern low-dose formulations (20–35 μg ethinyl estradiol) carry a smaller effect ○ SOURCED. Mechanism: hepatic angiotensinogen induction → RAAS activation.
• VEGF/VEGFR inhibitors — reduced NO and prostacyclin production, increased endothelin-1, capillary rarefaction, increased peripheral resistance. Often dose-limiting in oncology but "typically resolves with discontinuation of the provoking agent" ○ SOURCED. Bevacizumab was the first agent (approved 2004); the small-molecule TKIs sorafenib, sunitinib, pazopanib followed ○.
• Calcineurin inhibitors — "related to interference with the balance of vasoactive substances, including endothelin and nitric oxide", plus direct NCC activation via the WNK–SPAK pathway (mechanistically a pharmacologic Gordon syndrome, which is a lovely piece of convergence). Incidence 32–81% in renal transplant, ~100% in cardiac transplant recipients ○ SOURCED.
• Glucocorticoids — MR occupancy at high dose plus GR-mediated ENaC activation. Notably, a mouse model of Cushing syndrome showed both MR and GR stimulate ENaC activity ○ SOURCED — so the mechanism is not purely MR spillover.
• Sympathomimetics — direct α-adrenergic vasoconstriction (cocaine, amphetamines, decongestants, MAOI–tyramine interaction).
• Erythropoiesis-stimulating agents — increased viscosity, endothelin release, reversal of hypoxic vasodilation.

5.3 Infectious agents

Not a primary cause, but relevant paths exist: - Post-streptococcal glomerulonephritis (Streptococcus pyogenes, NCBITaxon:1314 △) → acute nephritic hypertension. - HIV-associated nephropathy (NCBITaxon:11676 △) → renal parenchymal hypertension. - Hepatitis B–associated polyarteritis nodosa → renovascular hypertension. - Chronic pyelonephritis with reflux nephropathy → parenchymal scarring → hypertension.

6. Mechanism / Pathophysiology

6.1 The causal chains — ordered, one step per line

Secondary hypertension is genuinely branched, so here are six chains rather than one. Each terminates in the shared node Elevated Systemic Arterial Pressure. → reads as "leads to". I mark inference where the step is extrapolated rather than directly demonstrated in humans.

CHAIN A — Autonomous mineralocorticoid excess (primary aldosteronism)

1. Somatic gain-of-function variant in KCNJ5, CACNA1D, ATP1A1, ATP2B3 (or germline FH variant) arises in an adrenal zona glomerulosa cell → loss of the resting hyperpolarized membrane potential.
2. Membrane depolarization → opening of voltage-gated Ca²⁺ channels → sustained rise in intracellular Ca²⁺.
3. Sustained intracellular Ca²⁺ → constitutive transcription of CYP11B2 (aldosterone synthase), uncoupled from angiotensin II and potassium.
4. Constitutive CYP11B2 activity → renin-independent aldosterone overproduction. (This is the defining lesion; Brown 2020 ✔ showed it exists as a continuum rather than a threshold.)
5. Aldosterone → binds the mineralocorticoid receptor (NR3C2) in the distal nephron principal cell.
6. MR activation → transcriptional induction of SGK1 → SGK1 phosphorylates NEDD4-2 → NEDD4-2 can no longer ubiquitinate ENaC ○ SOURCED.
7. Reduced ENaC turnover → increased ENaC surface density and open probability → increased apical Na⁺ entry.
8. Increased Na⁺ reabsorption → plasma volume expansion and, via the lumen-negative potential, K⁺ and H⁺ secretion → hypokalemia and metabolic alkalosis.
9. Volume expansion → elevated systemic arterial pressure, with reciprocal renin suppression (the biochemical fingerprint).
10. In parallel (not downstream of volume): MR activation in endothelium, vascular smooth muscle, cardiomyocytes, fibroblasts and macrophages → Nox1/p66Shc-mediated oxidative stress, pro-inflammatory and pro-fibrotic signaling ○ SOURCED → vascular stiffening, cardiac and renal fibrosis.
11. Step 10 → target-organ damage disproportionate to the BP level — the explanation for the excess cardiovascular risk in §11. Endothelial MR activation also raises endothelial sodium channel (EnNaC) activity, "an important mechanism by which cardiovascular stiffness is promoted by excess aldosterone" ○.

Branch point at step 4: unilateral (adenoma/APN — surgically curable) vs bilateral (idiopathic hyperaldosteronism — medically managed). This branch is the entire reason adrenal vein sampling exists.

CHAIN B — Renovascular hypertension (2-kidney-1-clip physiology)

1. Atherosclerotic plaque or fibromuscular dysplastic web narrows a renal artery → reduced perfusion pressure at the afferent arteriole.
2. Reduced afferent pressure sensed by the juxtaglomerular apparatus → renin release from JG cells.
3. Renin cleaves angiotensinogen → angiotensin I → ACE (pulmonary and endothelial) → angiotensin II.
4. Angiotensin II → AT1 receptor–mediated arteriolar vasoconstriction → raised systemic vascular resistance.
5. Angiotensin II → adrenal aldosterone release → Chain A steps 5–9 (sodium retention).
6. Angiotensin II → central sympathetic activation and thirst, plus vasopressin release.
7. Steps 4–6 → elevated systemic arterial pressure.
8. Critical branch: with one stenosed kidney, the contralateral kidney pressure-natriureses, so renin stays high and the hypertension remains renin-dependent — this is the state where revascularization works. With bilateral stenosis or a solitary kidney, sodium retention takes over, renin normalizes, and the hypertension becomes volume-dependent ○ SOURCED (directly demonstrated in the 2K1C vs 1K1C animal models, §15).
9. Chronic ischemia → tubulointerstitial fibrosis and atrophy → ischemic nephropathy → irreversibility. This is why late revascularization fails, and a plausible explanation for the negative CORAL/ASTRAL trial results.

CHAIN C — Glucocorticoid-mediated (Cushing syndrome; and its genetic phenocopy, AME)

1. Cortisol excess (pituitary ACTH adenoma, adrenal adenoma, ectopic ACTH, exogenous steroid) → plasma cortisol far above normal.
2. Cortisol binds MR with affinity equal to aldosterone ○ SOURCED; normally 11β-HSD2 protects the receptor by converting cortisol → inactive cortisone.
3. Severe cortisol excess → saturation of renal 11β-HSD2 → "a functional mineralocorticoid excess, due to the binding and activation of the mineralocorticoid receptor by excessive glucocorticoids" ○ SOURCED.
4. MR occupancy by cortisol → Chain A steps 6–9 → sodium retention, hypokalemia, volume expansion, hypertension.
5. Parallel GR-mediated arm: glucocorticoid receptor signaling also stimulates ENaC ○ SOURCED, plus increased hepatic angiotensinogen, enhanced vascular α-adrenergic reactivity, and suppressed NO and prostacyclin.
6. Genetic phenocopy: HSD11B2 loss-of-function reaches the identical step-3 state at normal cortisol levels — "'Cushing's disease of the kidney' results in cortisol-mediated mineralocorticoid excess" ○ SOURCED. Pharmacologic phenocopy: glycyrrhizic acid inhibits the same enzyme.

CHAIN D — Catecholamine excess (PPGL)

1. Germline or somatic driver (SDHx, VHL, RET, NF1, MAX, TMEM127) in a chromaffin progenitor → pseudohypoxic (cluster 1) or kinase-driven (cluster 2) tumorigenesis.
2. Clonal expansion of chromaffin cells → catecholamine-synthesizing tumor mass in adrenal medulla or extra-adrenal paraganglia.
3. Unregulated epinephrine, norepinephrine and/or dopamine synthesis and release ○ SOURCED — critically, release is not under normal neural control.
4. Norepinephrine → α1-adrenergic vasoconstriction → raised systemic vascular resistance; epinephrine → β1-mediated increases in heart rate and contractility → raised cardiac output.
5. Steps 4 → paroxysmal or sustained elevated arterial pressure with headache, palpitations, diaphoresis ○.
6. Chronic catecholamine exposure → downregulation of adrenergic receptors and reduced plasma volume → the orthostatic hypotension between paroxysms, and the profound hypotension on tumor devascularization if the patient has not been α-blocked and volume-repleted first. (This step is the mechanistic basis of the preoperative α-blockade requirement.)
7. Chronic catecholamine exposure → catecholamine cardiomyopathy, takotsubo-like injury, myocardial fibrosis.

CHAIN E — Obstructive sleep apnea

1. Upper airway collapsibility (anatomic and non-anatomic traits) → repetitive apnea/hypopnea during sleep.
2. Apnea → intermittent hypoxia and hypercapnia, plus repeated arousals and sleep fragmentation.
3. Chemoreceptor stimulation by intermittent hypoxia + arousal → sympathetic overactivity — "Sympathetic activity due to intermittent hypoxia and/or fragmented sleep is the most important mechanisms triggering the elevation in blood pressure in OSA" ✔ VERIFIED (Shiina 2024, PMID:39210083).
4. Sympathetic outflow → renal vasoconstriction and altered sodium handling → RAAS activation (a sympathetic–RAAS reinforcing loop) ○ SOURCED.
5. RAAS activation → aldosterone → Chain A steps 5–9 → fluid retention.
6. Fluid retention → nocturnal rostral fluid shift → increased peri-pharyngeal tissue pressure → worse airway collapsibility → back to step 1. A closed positive-feedback loop — this is why MRAs reduce both BP and the apnea–hypopnea index in this population ○ SOURCED.
7. Steps 3–5 → nocturnal hypertension, non-dipping/reverse-dipping BP pattern, exaggerated BP variability, vascular remodeling, resistant hypertension ✔.
8. Negative intrathoracic pressure swings against a closed airway → increased LV transmural pressure and afterload → an additional, purely mechanical contribution.

CHAIN F — Drug/toxin-induced (the VEGF-inhibitor exemplar)

1. Administration of a VEGF-A antibody or VEGFR tyrosine-kinase inhibitor → blockade of VEGFR2 signaling in vascular endothelium.
2. Loss of VEGFR2 signaling → reduced eNOS activation → reduced nitric oxide bioavailability, and reduced prostacyclin.
3. Reduced NO → loss of tonic vasodilation → increased arteriolar tone; concurrently increased endothelin-1 production.
4. Sustained VEGF blockade → capillary rarefaction (loss of microvascular density) → structurally increased peripheral resistance (inferred from preclinical models; human histologic confirmation is limited).
5. Steps 3–4 → increased systemic vascular resistance → elevated arterial pressure, typically within days to weeks of the first dose.
6. Drug withdrawal → reversal in most cases ○ SOURCED — the reversibility is what makes this a clean causal demonstration.

Parallel toxicologic chains: NSAID → COX-2 inhibition → reduced renal prostaglandin → reduced natriuresis → volume expansion. Calcineurin inhibitor → endothelin↑ / NO↓ plus WNK–SPAK–NCC activation → sodium retention. Both converge on the same terminal node.

6.2 Cross-cutting mechanistic themes

• Convergence on ENaC and NCC. Liddle (ENaC directly), PA (ENaC via SGK1/NEDD4-2), AME and Cushing (ENaC via unprotected MR), Gordon and calcineurin inhibitors (NCC via WNK–SPAK). Five etiologies, two transporters. This is the strongest argument that a mineralocorticoid_excess_sodium_retention-type mechanism module would earn its keep in dismech.
• Aldosterone is not just a volume hormone. The MR is expressed in endothelium, VSMC, cardiomyocytes, fibroblasts and myeloid cells. "Deletion of endothelial cell MRs prevents the development of vascular and cardiac fibrosis and stiffness" ○ SOURCED. Aldosterone induces damage via "MR-Nox1-p66Shc-mediated processes that modulate pro-fibrotic and pro-inflammatory signaling pathways" ○. This decoupling of pressure from injury is the mechanistic core of §11.
• Immune involvement. Myeloid-cell corticosteroid receptor signaling contributes to salt-sensitive hypertension; a 2024 preprint argues the effect runs through glucocorticoid, not mineralocorticoid, receptors in myeloid cells via cortisol ○ SOURCED (preprint — treat as a hypothesis, not established).
• Oxidative stress and NO deficiency are the shared tissue-injury currency: Nox1/Nox4-derived ROS in MR signaling, eNOS uncoupling in VEGFi and calcineurin-inhibitor hypertension, carotid-body ROS in intermittent hypoxia.

6.3 Ontology term leads

GO biological process (all △ — verify with runoak -i sqlite:obo:go): GO:0008217 regulation of blood pressure · GO:0003073 regulation of systemic arterial blood pressure · GO:0002018 renin-angiotensin regulation of aldosterone production · GO:0032342 aldosterone biosynthetic process · GO:0035813 regulation of renal sodium excretion · GO:0006814 sodium ion transport · GO:0048010 vascular endothelial growth factor receptor signaling pathway · GO:0006809 nitric oxide biosynthetic process · GO:0042311 vasodilation · GO:0042310 vasoconstriction

Cell Ontology (all △): juxtaglomerular cell · kidney distal convoluted tubule epithelial cell · kidney collecting duct principal cell · adrenal zona glomerulosa cell · chromaffin cell (CL:0000166 — reasonably confident, still verify) · endothelial cell (CL:0000115) · vascular smooth muscle cell · myofibroblast · macrophage

UBERON (all △): kidney (UBERON:0002113) · adrenal gland (UBERON:0002369) · adrenal cortex · adrenal medulla · renal artery · aorta · heart (UBERON:0000948) · retina · upper respiratory tract / pharynx

6.4 Molecular profiling

• Transcriptomics: APA transcriptomes cluster by driver genotype; KCNJ5-mutant tumors show a zona-fasciculata-like expression signature, wild-type/CACNA1D tumors a glomerulosa-like one. GEO holds multiple adrenal PA series — run just discover-datasets rather than trusting a recalled accession.
• Proteomics/metabolomics: steroid-profiling by LC-MS/MS is the most clinically mature "omics" here — 18-oxocortisol and 18-hydroxycortisol distinguish KCNJ5-mutant APA and GRA from other PA subtypes ○ SOURCED.
• Spatial / single-cell: CYP11B2 immunohistochemistry is effectively a low-plex spatial assay and has rewritten PA pathology (see §10.3). Single-cell adrenal atlases exist in the Human Cell Atlas.
• Functional genomics: no large disease-specific CRISPR screen; adrenal cell line (H295R) work dominates.

7. Anatomical Structures Affected

Primary (cause-bearing) sites — vary by etiology: - Adrenal cortex, zona glomerulosa — PA, CAH △ - Adrenal medulla and extra-adrenal paraganglia (organ of Zuckerkandl, carotid body, head-and-neck paraganglia) — PPGL △ - Pituitary gland, corticotroph — Cushing disease △ - Kidney: renal artery (renovascular), glomerulus and tubulointerstitium (parenchymal), distal convoluted tubule and collecting duct (monogenic tubulopathies) △ - Aorta, juxtaductal isthmus — coarctation △ - Upper airway, pharynx — OSA △ - Thyroid, parathyroid — endocrine causes △

Secondary (target-organ) sites — shared: - Heart — LV hypertrophy, diastolic dysfunction, heart failure, atrial remodeling and fibrillation - Brain — ischemic and hemorrhagic stroke, cerebral small-vessel disease, hypertensive encephalopathy - Kidney — hypertensive nephrosclerosis, albuminuria, CKD progression (kidney is both cause and casualty here, which makes the causal graph genuinely cyclic) - Retina — hypertensive retinopathy, arteriovenous nicking, hemorrhages, papilledema in malignant phase - Large arteries — stiffening, aneurysm, aortic dissection

Body systems: cardiovascular, renal/urinary, endocrine, nervous (autonomic and central), respiratory (OSA).

Tissue and cell level: vascular endothelium; vascular smooth muscle; renal tubular epithelium (distal convoluted tubule, connecting tubule, cortical collecting duct principal cells); adrenocortical zona glomerulosa cells; adrenal chromaffin cells; cardiac myocytes and fibroblasts; infiltrating macrophages and T cells.

Subcellular: apical plasma membrane (ENaC, NCC) △ GO:0016324 apical plasma membrane; nucleus (MR/GR nuclear receptor translocation) GO:0005634; mitochondrial inner membrane (CYP11B2 is a mitochondrial P450) GO:0005743; smooth ER (steroidogenesis); secretory/chromaffin granules (catecholamine storage).

Lateralization — genuinely important here, unusually so: - PA: unilateral vs bilateral is the treatment-determining question (surgery vs lifelong MRA), resolved by adrenal vein sampling. - Renal artery stenosis: unilateral (renin-dependent, revascularization-responsive) vs bilateral (volume-dependent). - PPGL: bilateral disease seen "exclusively in VHL carriers" in one series ○ — a lateralization finding with direct genetic-testing implications.

8. Temporal Development

Onset - Bimodal across the lifespan. In children <12, secondary causes account for 70–85% of all hypertension ○ SOURCED, overwhelmingly renal parenchymal. In young adults 18–40, 29.6% ✔. In middle age the secondary fraction is lowest. In the elderly it rises again with atherosclerotic RAS and polypharmacy. - Onset pattern by cause: acute (acute glomerulonephritis, drug initiation, PPGL crisis), subacute/insidious (PA, Cushing, OSA), congenital (coarctation, CAKUT, monogenic). - Red-flag onset patterns: hypertension before age 30 without family history or obesity; abrupt onset after age 55; sudden loss of control in previously stable hypertension; hypertensive emergency.

Progression and staging No formal staging system for the umbrella concept. Practically, three stages track reversibility:

1. Reversible / functional — the mechanism is active but tissue is intact. Full cure possible on correcting the cause.
2. Partially reversible — vascular remodeling, LVH and nephrosclerosis established. BP improves but does not normalize; drug burden falls.
3. Irreversible / autonomous — ischemic nephropathy, fixed nephrosclerosis, established target-organ damage. The hypertension has become self-sustaining and behaves like essential hypertension.

This staircase is the single most consequential temporal fact in the disease. Duration of hypertension before correction is the strongest predictor of cure after adrenalectomy or revascularization. Critical intervention window: early.

Course patterns - Sustained: PA, renal parenchymal, coarctation, monogenic. - Paroxysmal/episodic: PPGL (spells lasting minutes to an hour), also episodic on a sustained background in ~50%. - Nocturnal-predominant / non-dipping: OSA, CKD, primary aldosteronism ✔ (Shiina 2024 lists nocturnal hypertension and abnormal BP variability as OSA-hypertension features). - Cyclic: cyclic Cushing syndrome — rare, and a notorious cause of missed diagnosis. - Pregnancy-triggered: Geller syndrome.

Remission - Treatment-induced is the norm and is the point of the whole enterprise: adrenalectomy for unilateral PA, tumor resection for PPGL, transsphenoidal surgery for Cushing disease, angioplasty for FMD, coarctation repair, culprit-drug withdrawal. - Spontaneous remission is essentially unheard of, with the narrow exception of self-limited drug or toxin exposures.

9. Inheritance and Population

9.1 Epidemiology — and the estimate you choose determines your answer

Global hypertension baseline: ~1.28 billion adults aged 30–79 have hypertension; 46% are unaware, 42% are diagnosed and treated, and only 21% are controlled ○ SOURCED (WHO Global Report on Hypertension, September 2023).

Secondary hypertension as a fraction of that:

Primary aldosteronism specifically — where the numbers have moved most:

• PAPY study ✔ (Rossi GP et al., J Am Coll Cardiol 2006, PMID:17161262): 1,125 newly diagnosed hypertensives; "the prevalence of APA is high (4.8%)" with idiopathic hyperaldosteronism in a further 6.4% — roughly 11% total. Also concluded "the availability of AVS is essential for an accurate identification of the adrenocortical pathologies underlying PA."
• Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, Vaidya A. "The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study." Ann Intern Med 2020. PMID:32449886 ✔ — 1,015 participants across four academic centers. Biochemically overt PA prevalence: 11.3% in normotensive individuals, 15.7% stage 1, 21.6% stage 2, 22.0% resistant hypertension. The authors describe "a continuum of renin-independent aldosterone production" and conclude "The prevalence of primary aldosteronism is high and largely unrecognized."

That normotensive figure is the striking one. It reframes PA from a discrete rare tumor syndrome into a graded, continuous trait that begins before hypertension does — a paradigm shift with obvious implications for how the concept should be modeled.

The screening gap ○ SOURCED: PA accounts for ~5–10% of all hypertension and up to 20% of resistant hypertension, "yet screening rates among eligible patients remain below 2%." Under 2%. That is not a diagnostic problem, it's a behavioral one.

Other causes: - Symptomatic renal artery FMD: prevalence ~4/1000, accounting for <10% of renovascular hypertension ○ SOURCED; atherosclerosis is the leading RAS cause and FMD is second. - OSA: highly prevalent (roughly 1 billion adults worldwide with some degree, ~425 million moderate-to-severe ○), and hugely enriched in resistant hypertension. - PPGL: ~0.2–0.6% of hypertensive patients ○. - Cushing syndrome: incidence ~0.7–2.4 per million per year ○.

9.2 Inheritance

• The umbrella concept is not heritable — inheritance is a property of individual causes.
• Autosomal dominant: Liddle syndrome, GRA/FH-I, FH-II (CLCN2), FH-III (KCNJ5), PASNA (CACNA1D), Gordon syndrome (mostly), Geller syndrome, hypertension-with-brachydactyly, most PPGL syndromes (with SDHD and SDHAF2 showing paternal-only transmission due to imprinting — a real gotcha for counseling).
• Autosomal recessive: AME (HSD11B2), hypertensive CAH forms, KLHL3-recessive Gordon syndrome, ARPKD.
• X-linked: not a significant category.
• Multifactorial/polygenic: OSA-related and obesity-related hypertension.
• Penetrance: high for the hypertension phenotype in Liddle, GRA and AME; incomplete and age-dependent in PPGL syndromes (SDHB penetrance estimates have fallen substantially with unbiased ascertainment — historically ~70%, more recent estimates far lower, ~20–25% by age 60 ○).
• Expressivity: highly variable, notably in Gordon syndrome ("quite variable", with short stature, dental abnormalities and intellectual difficulties in some ○) and in SDHx carriers.
• Anticipation: not described.
• Germline mosaicism: reported in NF1; rare elsewhere.
• Founder effects: SDHD p.Asp92Tyr (Dutch), SDHB founder alleles in several populations, RET founder variants ○.
• Consanguinity: relevant for AME and recessive CAH — AME clusters in consanguineous populations.
• Carrier frequency: HSD11B2 pathogenic carriers are rare, but heterozygotes may show salt sensitivity — a legitimate "carriers aren't unaffected" observation.

9.3 Demographics

• Sex: female predominance in the young-adult secondary-hypertension cohort ✔ and strongly in FMD ○. OSA-related hypertension is male-predominant. PA is roughly balanced with sex-linked mutation spectra (see §4.2).
• Ancestry: CACNA1D somatic mutations more prevalent in Black males, KCNJ5 in Black females ○; KCNJ5 dominant in East Asian cohorts ○. Black patients have higher rates of low-renin/salt-sensitive hypertension generally.
• Geography: two-thirds of all hypertension burden is in low- and middle-income countries ○ (WHO 2023); secondary-cause detection is concentrated in high-income referral centers, so the geographic distribution of diagnosis is a health-system artifact, not biology. Worth stating explicitly in any epidemiology annotation.
• Age: bimodal — see §8.

10. Diagnostics

10.1 Who to screen — the 2025 guideline shift

✔ VERIFIED — Adler GK, Stowasser M, Correa RR, Khan N, Kline G, McGowan MJ, Mulatero P, Murad MH, Touyz RM, Vaidya A, Williams TA, Yang J, Young WF, Zennaro MC, Brito JP. "Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline." J Clin Endocrinol Metab. 2025. PMID:40658480. DOI:10.1210/clinem/dgaf284

The headline recommendation: "all individuals with hypertension be screened for PA by measuring aldosterone and renin." Also recommends "mineralocorticoid receptor antagonists (MRAs) over epithelial sodium-channel (ENaC) inhibitors", with spironolactone preferred on cost and availability. Note a published correction exists: PMID:40880123 ✔ (DOI:10.1210/clinem/dgaf472) — check it before quoting specific thresholds.

Its evidence base: ✔ Farah MH, Hegazi M, Firwana M, et al. "A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline on Management of Primary Aldosteronism." J Clin Endocrinol Metab 2025. PMID:40658500. DOI:10.1210/clinem/dgaf290 — 95 studies. Screening was "associated with higher rates of using PA-specific medical therapies and better blood pressure control." AVS improved surgical cure rates but increased hemorrhage risk. "Surgical therapy may be associated with better blood pressure control than medical therapy, with a lower number and dosage of antihypertensive medications." Spironolactone outperformed eplerenone for hypokalemia control.

2025 AHA/ACC hypertension guideline ○ SOURCED — expands PA screening to all patients with stage 2 or resistant hypertension regardless of serum potassium, plus unexplained hypokalemia, OSA, incidental adrenal mass, family history of early-onset hypertension, or stroke before age 40. Practically important: "all antihypertensive medications except mineralocorticoid receptor antagonists (MRA) should be continued to avoid unnecessary delays or barriers to screening." This removes the drug-washout step that historically killed most screening attempts.

And ✔ the young-adult study's own conclusion: "all patients with hypertension under 40 years of age should be screened for secondary causes" (PMID:39297209).

10.2 Test menu by cause

Cross-cutting: 24-h ambulatory BP monitoring (essential — establishes the diagnosis, detects non-dipping, excludes white-coat effect), ECG and echocardiography for LVH, fundoscopy.

10.3 Histopathology — CYP11B2 immunohistochemistry has redefined PA

This is a genuinely recent shift worth curating carefully.

"The introduction of CYP11B2 immunostaining led to the HISTALDO consensus classification into classical and non-classical histology. The 2022 WHO classification separated solitary aldosterone-producing adenomas/nodules (APA/APN; classical histology) from multiple nodules/micronodules (MAPN/MAPM; non-classical histology)" ○ SOURCED.

Consequences: - Classical histology (single dominant CYP11B2-positive lesion) → surgery usually curative. - Non-classical (multinodular) → "~40%–45% persistent biochemical aldosteronism" after surgery ○. - A refinement, the CYP11B2 size ratio (B2R): B2R ≥8.1 indicates classical histology with high cure likelihood; B2R <8.1 indicates non-classical multinodular disease with lower cure rates and higher recurrence risk ○ SOURCED (Stenman et al., Histopathology; and PMID:40729417 ○ "Improving diagnosis in primary aldosteronism using HISTALDO and nodule size metrics", Eur J Endocrinol 2025). - The caveat that keeps it honest: CYP11B2-positive micronodules are "common… in adrenals from non-PA patients" ○, so the assay does not cleanly separate disease from normal ageing adrenal nodularity. Model this as a diagnostic-uncertainty knowledge gap, not a settled criterion.

10.4 Genetic testing

• Gene panel is the right default for suspected monogenic hypertension. A registered "Monogenic Hypertension Genetic Panel" exists in NCBI GTR (test 592295 ○).
• PPGL: germline testing recommended for all patients regardless of family history, given the 25–40% germline rate ○. Panel covering SDHA/B/C/D/AF2, VHL, RET, NF1, MAX, TMEM127, FH.
• GRA/FH-I requires long-range PCR or MLPA for the chimeric gene — standard sequencing panels miss it. This is a common false-negative and worth an explicit note.
• WES/WGS: reserved for panel-negative, strongly suspicious cases.
• CMA/karyotype: for syndromic presentations (Turner syndrome).
• Cascade testing: indicated for all confirmed monogenic and PPGL-syndrome families.
• Somatic testing of resected APA tissue: research-grade today, but genotype predicts LV remodeling recovery ○ and may become prognostic.

10.5 Differential diagnosis

10.6 Screening

• No population-wide screening for secondary hypertension exists. Case-finding within a hypertensive population is the operative model, and per §10.1 the eligible population has been broadened dramatically.
• Newborn screening: 21-hydroxylase CAH is screened, but the hypertensive CAH forms (11β- and 17α-hydroxylase) are not captured by standard 17-OHP newborn screening. Worth noting explicitly.
• Cascade screening for monogenic and PPGL families.
• Pediatric BP measurement from age 3 is the practical screening entry point for the childhood renal causes.

11. Outcome / Prognosis

11.1 The central prognostic fact: secondary hypertension is worse than its blood pressure

✔ VERIFIED — Monticone S, D'Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, Mulatero P. "Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis." Lancet Diabetes Endocrinol. 2018. PMID:29129575

31 studies, 3,838 PA patients vs 9,284 essential-hypertension controls, median 8.8-year follow-up. Odds ratios vs essential hypertension:

Plus increased diabetes and metabolic syndrome. The authors: "Diagnosing primary aldosteronism in the early stages of disease, with early initiation of specific treatment, is important because affected patients display an increased cardiovascular risk compared with patients with essential hypertension."

Broader ranges reported elsewhere: 2.5–4× stroke, 2.6–6.5× non-fatal MI, 3.2–12× atrial fibrillation ○ SOURCED.

11.2 The finding that changes how you treat it

✔ VERIFIED — Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. "Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study." Lancet Diabetes Endocrinol. 2018. PMID:29129576

602 medically treated PA patients vs 41,853 age-matched essential-hypertension controls. Despite comparable blood pressure control, PA patients had cardiovascular events at 56.3 vs 26.6 per 1,000 person-years, plus higher mortality, diabetes and atrial fibrillation.

The mechanistic punchline: "excess risk was limited to patients whose renin remained suppressed during treatment; those receiving higher antagonist doses with unsuppressed renin showed no significant excess risk."

Read that carefully, because it's the whole ballgame. Normalizing the blood pressure is not the therapeutic target — un-suppressing the renin is. A suppressed renin on treatment means the MR is still occupied and still driving fibrosis and inflammation, whatever the cuff says. This is the clearest clinical demonstration anywhere that the pressure and the injury are separable, and it converts §6.2's mechanism into a dosing rule.

11.3 Recovery with cause-directed treatment

• Adrenalectomy for unilateral PA: "markedly superior outcomes over medical therapy, yielding an absolute risk reduction in all-cause mortality that rivals or exceeds many major cardiovascular surgeries" ○ SOURCED. Also lowers incident atrial fibrillation long-term ○ (PMID:29483224 ○). Complete clinical success (cure of hypertension off all drugs) in roughly a third; biochemical cure in the large majority. Predictors of cure: shorter hypertension duration, younger age, female sex, fewer antihypertensives, classical HISTALDO histology / B2R ≥8.1 ○.
• FMD revascularization: hypertension cure 46% (95% CI 40–52%) after angioplasty and 58% (95% CI 53–62%) after surgery ○ SOURCED. Genuinely curative in a way atherosclerotic RAS is not.
• Atherosclerotic RAS: CORAL and ASTRAL failed to show benefit of revascularization over medical therapy — and, importantly for interpretation, "Patients with fibromuscular dysplasia were not part of the CORAL trial" ○. Do not generalize CORAL to FMD. That is a Named-Entity-Confusion trap sitting right in the literature.
• CPAP for OSA: modest BP reduction, "typically 2–5 mmHg", greater in resistant hypertension, obesity, and high adherence ○ SOURCED. CPAP alone rarely suffices — "often requiring additional antihypertensive medications" ✔ (Shiina 2024).
• Drug-induced: usually fully reversible on withdrawal ○.
• Coarctation repair: high rate of persistent or recurrent hypertension even after successful anatomic repair, especially with late repair — an important expectation-setting fact.

11.4 Mortality

• Untreated PA: "10–20% higher mortality rates over 5–10 years compared to essential hypertension" ○ SOURCED (a modeled/aggregate estimate — flag as such).
• Malignant/accelerated hypertension carries very poor untreated survival (historically ~20% at 1 year) with dramatic improvement on treatment ○.
• PPGL: benign resected disease has near-normal survival; metastatic disease (higher risk with SDHB) has 5-year survival ~40–60% ○.
• Untreated Cushing syndrome: ~4–5× standardized mortality ratio, normalizing with remission ○.

11.5 Prognostic factors

Duration of hypertension before diagnosis (dominant) · age at diagnosis · degree of target-organ damage at presentation · on-treatment renin (PA — ✔ Hundemer) · APA histology class and B2R ○ · APA driver genotype (KCNJ5 → better LV recovery ○) · lateralization (unilateral vs bilateral) · baseline eGFR · SDHB status in PPGL.

12. Treatment

12.1 Governing principle

Treat the cause, then treat the pressure. Everything below is downstream of that. Where the cause is correctable, generic antihypertensive therapy is a bridge, not a destination.

12.2 Cause-directed treatment

Note the pattern in the last five rows. Each monogenic syndrome has a mechanistically matched drug that works far better than generic therapy, and in Liddle's and Geller's cases the "obvious" drug (spironolactone) is useless or actively harmful. This is precision medicine in its oldest and least glamorous form, and it's a strong argument for genotyping.

12.3 Pharmacotherapy — agents

Mineralocorticoid receptor antagonists: spironolactone (steroidal, non-selective — gynecomastia, menstrual irregularity), eplerenone (selective, weaker, twice-daily), finerenone (non-steroidal, approved for CKD in T2D — cardiorenal rather than antihypertensive indication), esaxerenone. Guideline preference: MRAs over ENaC inhibitors, spironolactone first ✔ (PMID:40658480).

ENaC inhibitors: amiloride, triamterene. First-line specifically for Liddle syndrome.

Standard classes as adjuncts: ACE inhibitors/ARBs (caution and monitoring in bilateral RAS), calcium channel blockers, thiazides, β-blockers (never before α-blockade in PPGL — unopposed α-stimulation precipitates crisis), α-blockers (phenoxybenzamine, doxazosin) for PPGL preparation.

Pharmacogenomics: CYP3A5 expressor status affects tacrolimus exposure and therefore CNI-hypertension risk; CYP2C9/VKORC1 relevant to anticoagulation in the AF complications rather than to BP itself; spironolactone has no established PGx gate. PharmGKB is the place to check.

12.4 Recent and emerging therapeutics (2023–2026)

Aldosterone synthase inhibitors — the most consequential new mechanism in decades. These inhibit CYP11B2 directly, cutting aldosterone at the source rather than blocking its receptor, with the design challenge being selectivity over the 93%-identical CYP11B1 (cortisol synthase) to avoid adrenal insufficiency.

• ✔ VERIFIED — Freeman MW, Halvorsen YD, Marshall W, Pater M, Isaacsohn J, Pearce C, Murphy B, Alp N, Srivastava A, Bhatt DL, Brown MJ; BrigHTN Investigators. "Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension." N Engl J Med. 2023. PMID:36342143. 248 patients on ≥3 antihypertensives. "Dose-dependent changes in systolic blood pressure of -20.3 mm Hg, -17.5 mm Hg, -12.1 mm Hg, and -9.4 mm Hg were observed in the 2-mg, 1-mg, 0.5-mg, and placebo groups, respectively." The 2-mg dose beat placebo by -11.0 mm Hg (P<0.001), with selective aldosterone reduction and no adrenocortical insufficiency. "No deaths occurred during the trial, no serious adverse events were attributed by the investigators to baxdrostat."
• The honest counterweight ✔ — Dey S, Frishman WH, Aronow WS. "Baxdrostat: An Aldosterone Synthase Inhibitor for the Treatment of Systemic Hypertension." Cardiol Rev. 2025. PMID:37548462. "An increased level of aldosterone is associated with inflammation, systemic hypertension, and organ fibrosis, contributing to adverse cardiovascular events." But: "the subsequent HALO trial failed to demonstrate blood pressure-lowering benefits compared to placebo." Do not curate baxdrostat as an unqualified success — BrigHTN was positive, HALO was not, and reconciling them (dosing, adherence, population) is an open question.
• Baxdrostat in PA specifically: a Phase 2a study, NEJM 2025 ○ — 15 PA patients, resolved or reduced hypertension, aldosterone excess, and hypokalemia.
• ✔ VERIFIED — Laffin LJ, Kopjar B, Melgaard C, Wolski K, Ibbitson J, Bhikam S, Weir MR, Ofili EO, Mehra R, Luther JM, Cohen DL, Sarraju A, Wilkinson MJ, Flack JM, Rodman D, Nissen SE; Advance-HTN Investigators. "Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension." N Engl J Med. 2025. PMID:40267417. DOI:10.1056/NEJMoa2501440. 285 participants. At 12 weeks, systolic BP fell 15.4 mm Hg (stable 50 mg) and 13.9 mm Hg (dose-adjusted) vs 7.4 mm Hg placebo. Hyperkalemia in 5–7% of lorundrostat recipients vs none on placebo — the expected class toxicity, and the thing to monitor. Conclusion: "Lorundrostat was associated with greater reductions in 24-hour average blood pressure than placebo."
• Related: Launch-HTN and Target-HTN lorundrostat programs ○; a review of the class, PMID:38358268 ✔ (Feldman, Frishman, Aronow, Cardiol Rev).

Renal denervation — two systems FDA-approved in November 2023 ○ SOURCED, ten days apart: ReCor Medical's ultrasound Paradise system (advisory panel voted unanimously on safety, 8–3 on efficacy) and Medtronic's radiofrequency Symplicity Spyral. Both carry broad indications for hypertension when lifestyle change and drugs fail. Relevant trial: ✔ Townsend RR, Ferdinand KC, Kandzari DE, Kario K, Mahfoud F, Weber MA, Schmieder RE, Pocock S, Tsioufis K, David S, Steigerwalt S, Walton A, Hopper I, Bertolet B, Sharif F, Fengler K, Fahy M, Hettrick DA, Brar S, Böhm M. "Impact of Antihypertensive Medication Changes After Renal Denervation Among Different Patient Groups: SPYRAL HTN-ON MED." Hypertension. 2024. PMID:38314554. Note RDN targets the sympathetic limb, so it is mechanistically aimed at Chain E and neurogenic hypertension rather than at mineralocorticoid excess — an important scoping point when linking treatments to mechanism nodes.

Other emerging: zilebesiran (siRNA against hepatic AGT, ~6-monthly dosing — note the several angiotensinogen-iRNA patents that surfaced in searching, which is a signal of how active this space is); endothelin antagonists (aprocitentan, approved for resistant hypertension); SGLT2 inhibitors and GLP-1/GIP receptor agonists as adjuncts, "may benefit patients with nocturnal and obesity-related hypertension" ✔ (Shiina 2024).

12.5 Adverse events

Spironolactone: hyperkalemia, gynecomastia (dose-dependent, up to ~10%), menstrual irregularity, AKI. ASIs: hyperkalemia (5–7% ✔), hyponatremia, theoretical cortisol suppression (not observed at effective baxdrostat doses ✔). Phenoxybenzamine: profound orthostatic hypotension, reflex tachycardia, nasal congestion. Adrenalectomy: hemorrhage, adrenal insufficiency if bilateral. AVS: hemorrhage/adrenal vein rupture ✔ (Farah 2025). Renal angioplasty: dissection, restenosis, atheroembolism. RDN: access-site complications, rare renal artery stenosis (FDA MAUDE analysis exists ○).

12.6 Treatment algorithm (synthesized)

1. Confirm hypertension with out-of-office BP. Exclude pseudoresistance and non-adherence.
2. Screen by risk profile — and note that the risk profile is now very wide: all hypertensives for PA per the Endocrine Society ✔, all under-40s for secondary causes generally ✔, stage 2/resistant per AHA/ACC ○.
3. Structured medication and supplement review. Do this first — it costs nothing.
4. Baseline: electrolytes, creatinine/eGFR, urinalysis + ACR, TSH, calcium, ECG, ABPM.
5. ARR (continuing all drugs except MRAs ○). If positive → confirmatory testing → CT → AVS if surgery is contemplated.
6. Targeted testing driven by phenotype: metanephrines, cortisol screen, renal imaging, polysomnography.
7. Genetic panel if young onset, family history, or a suppressed-renin/suppressed-aldosterone biochemical signature.
8. Cause-directed definitive treatment (§12.2).
9. Residual hypertension → guideline combination therapy, with MRA as the preferred fourth agent in resistant hypertension.
10. Titrate to unsuppressed renin in PA, not merely to target BP ✔ (Hundemer 2018) — the most under-implemented recommendation in this whole field.
11. Consider ASI or renal denervation for genuinely refractory cases.

13. Prevention

Primary prevention — mostly not applicable to the genetic and neoplastic causes. Where it applies: - Sodium restriction and potassium-rich diet (blunts every mineralocorticoid mechanism). - Weight management → prevents OSA and obesity-associated aldosterone excess. - Avoid/limit the pressor drug classes; use the lowest effective NSAID dose and duration. - Avoid chronic liquorice ingestion (and be aware it hides in confectionery, teas and some tobacco products). - Atherosclerosis risk-factor control → prevents atherosclerotic RAS. - Occupational lead and cadmium controls. - Alcohol moderation.

Secondary prevention (early detection) — this is where the leverage is, given screening rates below 2% ○: - Systematic PA screening per the 2025 guidelines ✔. - Screen every hypertensive under 40 ✔. - Pediatric BP measurement from age 3. - Cascade genetic screening in monogenic and PPGL families; biochemical + imaging surveillance for SDHx carriers, beginning in childhood for SDHB. - Prenatal/preimplantation testing available for monogenic forms — a genetic-counseling conversation, not a routine offer.

Tertiary prevention (preventing complications in established disease): - Achieve and biochemically confirm cause-directed control — the on-treatment renin target ✔. - Statins, glycemic control, smoking cessation. - Post-adrenalectomy and post-coarctation-repair surveillance for recurrence. - Lifelong BP monitoring after any "cure" — cure is frequently partial.

Immunization: not applicable, except indirectly (streptococcal and hepatitis B vaccination reduce post-infectious glomerulonephritis and HBV-PAN routes).

Genetic counseling: essential for all monogenic forms and PPGL syndromes. Flag the imprinting quirk — SDHD and SDHAF2 transmit disease only from the father, and a counselor who misses that gives wrong risk figures to half the family.

Public health: population sodium reduction (reformulation, labeling), the WHO HEARTS package, air-pollution and noise abatement, lead abatement. WHO estimates 76 million deaths could be averted 2023–2050 with scaled-up hypertension coverage ○.

14. Other Species / Natural Disease

This section has a genuinely underappreciated star: the cat.

Orthologous genes: Kcnj5, Cacna1d, Scnn1b, Scnn1g, Hsd11b2, Nr3c2, Cyp11b2, Wnk1, Wnk4, Klhl3, Cul3, Ren, Agt, Ace — all conserved across mammals. Resolve NCBI Gene IDs via the Alliance of Genome Resources rather than by recall.

Comparative pathology: the RAAS is deeply conserved across vertebrates; renin-angiotensin regulation of blood pressure and sodium is present from fish onward. This makes the mechanisms of Chains A, B and C highly translatable. The mechanisms of Chain E (OSA) translate poorly — humans' unique upper-airway anatomy and bipedal fluid dynamics have no clean animal counterpart, which is precisely why OSA models rely on artificial intermittent-hypoxia chambers rather than spontaneous airway collapse.

Zoonotic potential: none. Not transmissible.

Look up OMIA for the feline hyperaldosteronism and canine pheochromocytoma entries before curating — I did not resolve OMIA IDs here.

15. Model Organisms

15.1 Surgical / induced models

Two-kidney-one-clip (2K1C) Goldblatt — the canonical renovascular model - Method: silver clip on one renal artery, contralateral kidney intact. "Induces renal ischemia and decreases renal blood flow, and the activation of the renin-angiotensin system in the clipped kidney is the most important mechanism contributing to its development" ○ SOURCED. "The development of 2K1C Goldblatt hypertension is associated with marked increases in renin expression and angiotensin II generation in the clipped kidney and their release into circulation" ○. - Species: originally dogs (Goldblatt, early 1930s), then rats, now well established in mice ○. - Fidelity: HIGH for human unilateral renal artery stenosis. It reproduces the renin-dependence, the two-phase course, and the therapeutic response to RAAS blockade. - Key validation: "Angiotensin II is a necessary component for the development of hypertension in the two kidney, one clip rat" ○ (PMID:6280481 ○). Also: "Genetic Deletion of AT1a Receptor or Na+/H+ Exchanger 3 Selectively in the Proximal Tubules of the Kidney Attenuates Two-Kidney, One-Clip Goldblatt Hypertension in Mice" ○ — a clean tubule-specific mechanistic dissection. - Limitations: an abrupt mechanical clip is not slowly progressive atherosclerotic stenosis; no atherosclerotic milieu; young healthy animals; rodent renal physiology differs in renin handling.

One-kidney-one-clip (1K1C) — the volume-dependent counterpart - "The one-kidney, one-clip model of Goldblatt renovascular hypertension is non-renin-dependent, while the two-kidney, one-clip Goldblatt hypertensive rat is renin-dependent, in which vascular hypertrophy is less severe" ○ SOURCED. - This pair is scientifically gorgeous: the same lesion produces renin-dependent or volume-dependent hypertension purely as a function of whether a pressure-natriuresing kidney remains. It is the direct experimental basis for the Chain B step-8 branch, and it explains at the bench why bilateral RAS behaves differently from unilateral. Fidelity: HIGH for bilateral disease / solitary kidney.

DOCA-salt - Method: uninephrectomy + deoxycorticosterone acetate + high-salt drinking water. - Models mineralocorticoid-excess hypertension — the closest induced analogue of PA and AME. Low-renin, volume-dependent, with prominent vascular and cardiac fibrosis and inflammation. - Fidelity: MODERATE-HIGH for the mineralocorticoid mechanism; the uninephrectomy and supraphysiological steroid dose are the main departures from human disease.

Chronic angiotensin II infusion (osmotic minipump) - Models Ang-II-driven hypertension with vascular inflammation, immune-cell infiltration and cardiac remodeling. The workhorse for the immune-mechanism literature. - Fidelity: MODERATE — supraphysiological, non-physiologically-regulated Ang II delivery.

Chronic intermittent hypoxia (CIH) — for OSA (Chain E). Cyclic hypoxia chambers reproduce sympathetic activation, carotid-body sensitization and BP elevation. Fidelity: MODERATE, with a large caveat: reproduces the hypoxia limb but not airway collapse, negative intrathoracic pressure swings, arousals, or the rostral-fluid-shift loop. This is a textbook PARTIALLY_RECAPITULATES with a HUMAN_MODEL_MISMATCH attached.

15.2 Genetic models

15.3 In vitro and NAM systems

• H295R human adrenocortical carcinoma line — the standard system for aldosterone synthesis, CYP11B2 regulation, and driver-mutation functional testing (Cellosaurus lookup needed for the accession).
• Primary human adrenal cell culture; adrenal organoids (emerging).
• Xenopus oocyte and HEK293 electrophysiology for ENaC, NCC, KCNJ5, CACNA1D variant function — the workhorse for variant classification.
• Human iPSC-derived vascular endothelial cells and endothelial-cell-on-chip for VEGFi and calcineurin-inhibitor vascular toxicity — the most directly relevant NAM for the drug-induced chains, and worth prioritizing given the toxicology framing.
• Precision-cut kidney slices for tubular transport.

15.4 Databases

MGI · RGD (especially strong for hypertension — RGD hosts a dedicated hypertension disease portal) · Alliance of Genome Resources · IMPC · IMSR · MMRRC · Cellosaurus · OMIA (for the veterinary natural disease in §14).

Appendix A — Curation notes for dismech

Some things I noticed while assembling this that bear on how the entry should be built. Take or leave.

1. This concept is probably a GROUPING, not a DISEASE. Per the project's own lump/split rules, GROUPING means "a union of distinct diseases." Secondary hypertension is exactly that — primary aldosteronism, pheochromocytoma, renal artery stenosis and VEGF-inhibitor toxicity share no mechanism, only an endpoint. The existing kb/disorders/Secondary_Hypertension.yaml (171 lines) is already curated narrowly around the drug-induced/VEGF branch, which suggests the same tension. Options: keep the disease entry scoped to drug/toxin-induced secondary hypertension and add kb/groupings/Secondary_Hypertension.yaml as the union, or promote the whole thing to a grouping. Either way, worth a deliberate decision rather than drift.

2. There is real module material here. The strongest candidate is a mineralocorticoid-excess / distal-nephron sodium-retention module: MR activation → SGK1 → NEDD4-2 phosphorylation → ENaC stabilization → sodium retention → volume expansion, with a parallel MR–Nox1–fibrosis arm. It would take conformers from PA, AME, Cushing, Liddle, liquorice toxicity, and hypertensive CAH — six diseases, one chain. A second candidate: VEGF-pathway-inhibitor vascular toxicity (NO deficit + endothelin + capillary rarefaction), which would sit naturally in the treatment-toxicity family alongside the existing entries.

3. Existing neighbours in the KB that this entry should connect to: Essential_Hypertension, Familial_Hyperaldosteronism, Familial_Hyperaldosteronism_Type_I, Pheochromocytoma_Paraganglioma, Hereditary_Pheochromocytoma-Paraganglioma_Syndrome, Cushings_Syndrome, Cushing_Disease, Obstructive_Sleep_Apnea, Hypertensive_Heart_Disease, Hypertensive_Retinopathy. There is also an open stub at stubs/Primary_Aldosteronism.yaml — given that PA is 54.8% of secondary hypertension ✔ and has moved more in the last three years than anything else here, that stub looks like the highest-value thing in the queue adjacent to this work.

4. Before any of this becomes YAML: every CURIE marked △ needs runoak/just validate-terms confirmation, and every quoted string needs just fetch-reference PMID:x plus just count-verified-snippets. The quotes in this report passed through a summarizing layer. Two PMIDs I probed came back as completely unrelated papers, which is the whole argument for not trusting a plausible-looking identifier.

5. Genuine knowledge gaps worth recording as discussions: - The BrigHTN/HALO discordance for baxdrostat ✔ — positive phase 2, negative follow-on, unreconciled. - CYP11B2-positive micronodules in non-PA adrenals ○ — the histologic criterion does not cleanly separate disease from ageing. - Epigenetic mechanisms across the board — thin, mostly candidate-level. - Whether the "renin-independent aldosteronism continuum" ✔ (Brown 2020) means PA should be modeled as a graded trait rather than a categorical disease. That's a nosology question dismech is unusually well-placed to represent, and it isn't settled anywhere else either. - CIH models capture the hypoxia limb of OSA but not the mechanical or fluid-shift limbs — a clean HUMAN_MODEL_MISMATCH.

Sources

PubMed records verified directly via NCBI E-utilities (✔): - PMID:39297209 — Prevalence and Risk Factors for Secondary Hypertension in Young Adults, Hypertension 2024 - PMID:32449886 — The Unrecognized Prevalence of Primary Aldosteronism, Ann Intern Med 2020 - PMID:29129575 — Cardiovascular events and target organ damage in primary aldosteronism, Lancet Diabetes Endocrinol 2018 - PMID:29129576 — Cardiometabolic outcomes and mortality in medically treated primary aldosteronism, Lancet Diabetes Endocrinol 2018 - PMID:17161262 — A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients (PAPY), JACC 2006 - PMID:18445663 — Body mass index predicts plasma aldosterone concentrations, JCEM 2008 - PMID:40658480 — Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline, JCEM 2025 - PMID:40658500 — Systematic Review Supporting the Endocrine Society PA Guideline, JCEM 2025 - PMID:40880123 — Correction to the Endocrine Society PA Guideline, JCEM 2025 - PMID:36342143 — Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension (BrigHTN), NEJM 2023 - PMID:37548462 — Baxdrostat: An Aldosterone Synthase Inhibitor, Cardiol Rev 2025 - PMID:40267417 — Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension (Advance-HTN), NEJM 2025 - PMID:38358268 — Emerging Therapies for Treatment-Resistant Hypertension: Lorundrostat and Related ASIs, Cardiol Rev - PMID:38314554 — SPYRAL HTN-ON MED antihypertensive medication changes after renal denervation, Hypertension 2024 - PMID:39210083 — Obstructive sleep apnea-related hypertension, Hypertens Res 2024

Other sources consulted (○): - Prevalence and Risk Factors for Secondary Hypertension in Young Adults — full text PDF, AHA Journals - Genetics of Primary Aldosteronism — Hypertension - KCNJ5 Somatic Mutations in Aldosterone-Producing Adenoma — Hypertension - Prevalence and clinical correlates of somatic mutation in aldosterone producing adenoma — Taiwanese population, Sci Rep - Shifting paradigms in primary aldosteronism — Front Endocrinol 2024 - Broadening Primary Aldosteronism Screening: Alignment Across Contemporary Guidelines — Hypertension - Updates in the 2025 AHA/ACC Hypertension Guideline — Curr Hypertens Rep - New ACC/AHA Guideline Addresses Prevention, Detection, Evaluation and Management of High Blood Pressure — ACC - Overview of Monogenic or Mendelian Forms of Hypertension — Front Pediatr - The Molecular Genetics of Gordon Syndrome — PMC - Monogenic Hypertension Genetic Panel — NCBI GTR - Pheochromocytoma and paraganglioma: implications of germline mutation investigation — PMC - Germline genetic variants in pheochromocytoma/paraganglioma — Endocrine Oncology 2023 - The hypertension of Cushing's syndrome — J Hypertens - Mineralocorticoid and Glucocorticoid Receptors Stimulate ENaC in a Mouse Model of Cushing Syndrome — Hypertension - Endocrine hypertension – Cushing's syndrome — PMC - Mineralocorticoid antagonists and ENaC inhibitors in hyperaldosteronism — PMC - ENaC in Salt-Sensitive Hypertension: Kidney and Beyond — Curr Hypertens Rep - Vascular dysfunction and fibrosis in SHRSP: the aldosterone-MR-Nox1 axis — PMC - Efficacy of Revascularization For Renal Artery Stenosis Caused by Fibromuscular Dysplasia — Hypertension - Atherosclerotic renal artery stenosis in the post-CORAL Trial Era — ScienceDirect - Long Term Outcomes After Renal Revascularization for Atherosclerotic Renovascular Disease (ASTRAL) — PMC - Drug induced hypertension – An unappreciated cause of secondary hypertension — ESH - Drug-Induced Hypertension: Focus on Mechanisms and Management — Curr Hypertens Rep - Comprehensive analysis of VEGF/VEGFR inhibitor-induced immune-mediated hypertension — PMC - Major Adverse Cardiovascular Events in Primary Aldosteronism After Adrenalectomy or MRA Treatment — JAHA - Primary aldosteronism: adrenalectomy could save more lives — PMC - Improving diagnosis in primary aldosteronism using HISTALDO and nodule size metrics — Eur J Endocrinol 2025 - Histopathological stratification of primary aldosteronism using the CYP11B2 size ratio — Histopathology - Clinical significance of CYP11B2 immunostaining in unilateral primary aldosteronism — PMC - Two-Kidney, One Clip and One-Kidney, One Clip Hypertension in Mice — Hypertension - Genetic Deletion of AT1a Receptor or NHE3 in Proximal Tubules Attenuates 2K1C Hypertension — PMC - Childhood Hypertension: A Retrospective Analysis of Causes, Treatments, and Complications — PMC - Overview of Endocrine Hypertension — Endotext, NCBI Bookshelf - Secondary Hypertension — StatPearls Point of Care - WHO — First WHO report details devastating impact of hypertension and ways to stop it (2023) - WHO Hypertension fact sheet - FDA Approves Paradise Renal Denervation System — TCTMD - Symplicity Spyral Approved: FDA Clears Second Renal Denervation System — TCTMD - EBI OLS4 — MONDO term resolution

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.